Targets › LYPLA1
1 program from 1 company in 5 trials: 3 Phase 1, 1 Phase 3, 1 Phase 2; Gastroenterology, Other, Respiratory; next expected readout Dec 2026.
Acts as an acyl-protein thioesterase. Hydrolyzes fatty acids from S-acylated cysteine residues in proteins such as trimeric G alpha proteins or HRAS. Acts as a palmitoyl thioesterase that catalyzes depalmitoylation of proteins, such as ADRB2, KCNMA1 and SQSTM1. (UniProt, O75608)
Open in Phaseline: the race on LYPLA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Boehringer Ingelheim | Verducatib (BI 1291583) Lysophospholipase A1 (LYPLA1) inhibitor | LYPLA1 | Phase 3 | Bronchiectasis; Healthy | Dec 2026 |
Healthy (3) Bronchiectasis (2)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.